Company Description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform.
It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.
The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever.
It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute.
GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
| Country | United States |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 17 |
| CEO | David Dodd |
Contact Details
Address: 1900 Lake Park Drive, Suite 380 Smyrna, Georgia 30080 United States | |
| Phone | 678 384 7220 |
| Website | geovax.com |
Stock Details
| Ticker Symbol | GOVX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000832489 |
| CUSIP Number | 373678507 |
| ISIN Number | US3736786068 |
| Employer ID | 87-0455038 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Alan Dodd | Chairman, President and Chief Executive Officer |
| Dr. Mark J. Newman Ph.D. | Chief Scientific Officer |
| Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Medical Officer |
| Dr. Harriet Latham Robinson Ph.D. | Founder, Chief Scientific Officer Emeritus and Member of Scientific Advisory Board |
| Mark W. Reynolds CPA | Chief Financial Officer and Corporate Secretary |
| Thomas O'Brien | Vice President of Quality Systems and Compliance |
| Jeffrey Welch | Head of Process Development and Manufacturing Operations |
| John Niles | Head of Commercial Operations |
| Dr. John W. Sharkey Ph.D. | Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 424B3 | Prospectus |
| Nov 12, 2024 | 424B3 | Prospectus |
| Nov 12, 2024 | 424B3 | Prospectus |
| Nov 12, 2024 | 424B3 | Prospectus |
| Nov 12, 2024 | 424B3 | Prospectus |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Oct 16, 2024 | 8-K | Current Report |